DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07415954

RecruitingPhase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

63

Recruiting sites

44

Enrollment

270

estimated

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 7-10%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07415954
Org study IDNN9662-8160
Secondary ID2025-523260-20European Medical Agency (EMA)
Secondary IDU1111-1324-0310World Health Organization (WHO)

Timeline

Milestones

Study first posted2026-02-17actual
Study start2026-04-17actual
Last update posted2026-05-19actual
Primary completion2027-09-03estimated
Study completion2027-10-01estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Male or female (sex at birth).
•Age 18-75 years (both inclusive) at the time of signing the informed consent.
•Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole [mmol/mol]) (both inclusive) as assessed by central laboratory at screening.
•Willingness to obtain a high weight loss (greater than [>] 25% of weight at baseline).

Exclusion criteria

•Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
•Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
•Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

Endpoints (17)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
5
Cardiometabolic biomarkers
5
Weight & body composition
4
Renal / kidney
2
Safety / tolerability / PK
1

Weight & body composition

4 endpoints
Secondary/protocol endpoint

Relative change in body weight

Time frame:From baseline (week 0) to (week 40)

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change in body weight

Time frame:From baseline (week 0) to (week 40)

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change in Body Mass Index (BMI)

Time frame:From baseline (week 0) to (week 40)

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change in waist circumference

Time frame:From baseline (week 0) to (week 40)

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

5 endpoints
Primary/protocol endpoint

Change in glycated haemoglobin (HbA1c) (week 16)

Time frame:From baseline (week 0) to week 16

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Primary/protocol endpoint

Change in HbA1c (week 28)

Time frame:From baseline (week 0) to week 28

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Primary/protocol endpoint

Change in HbA1c (week 40)

Time frame:From baseline (week 0) to week 40

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in HbA1c

Time frame:From baseline (week 0) to (week 16, 28 and 40)

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Change in Fasting Plasma Glucose (FPG)

Time frame:From baseline (week 0) to (week 16, 28 and 40)

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Renal / kidney

2 endpoints
Secondary/protocol endpoint

Change in Urine Albumin Creatinine Ratio (UACR)

Time frame:From baseline (week 0) to (week 16, 28 and 40)

uACR, change

ratio, improvement

LOINC 9318-7

Secondary/protocol endpoint

Change in estimated Glomerular Filtration Rate (eGFR) (creatinine cystatin C-based Chronic Kidney Disease-Epidemiology Collaboration [CKD-EPI] 2021)

Time frame:From baseline (week 0) to (week 40)

eGFR, change

change from baseline, improvement

LOINC 98979-8

Cardiometabolic biomarkers

5 endpoints
Secondary/protocol endpoint

Change in high sensitivity C-Reactive Protein (hsCRP)

Time frame:From baseline (week 0) to (week 40)

hs-CRP, change

ratio, improvement

LOINC 30522-7

Secondary/protocol endpoint

Change in total cholesterol

Time frame:From baseline (week 0) to (week 40)

Total cholesterol, change

ratio, improvement

LOINC 2093-3

Secondary/protocol endpoint

Change in High-Density Lipoprotein (HDL) cholesterol

Time frame:From baseline (week 0) to (week 40)

HDL-C, change

ratio, improvement

LOINC 2085-9

Secondary/protocol endpoint

Change in Low-Density Lipoprotein (LDL) cholesterol

Time frame:From baseline (week 0) to (week 40)

LDL-C, change

ratio, improvement

LOINC 13457-7

Secondary/protocol endpoint

Change in triglycerides

Time frame:From baseline (week 0) to (week 40)

Triglycerides, change

ratio, improvement

LOINC 2571-8

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Number of adverse events

Time frame:From baseline (week 0) to (week 44)

Treatment-emergent AEs (any)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.